{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:13:52Z","timestamp":1786374832440,"version":"build-2736575974"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.2459\/jcm.0b013e3283249aee","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T08:52:37Z","timestamp":1283331157000},"page":"446-453","source":"Crossref","is-referenced-by-count":2,"title":["New anticoagulants for atrial fibrillation"],"prefix":"10.2459","volume":"10","author":[{"given":"Raffaele","family":"De Caterina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Dalby","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Renda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210207","first-page":"1979","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation)","volume":"27","author":"Fuster","year":"2006","journal-title":"Eur Heart J"},{"key":"R2-2-20210207","doi-asserted-by":"crossref","first-page":"194S","DOI":"10.1378\/chest.119.1_suppl.194S","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"119","author":"Albers","year":"2001","journal-title":"Chest"},{"key":"R3-2-20210207","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/01.CIR.84.2.469","article-title":"Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy","volume":"84","author":"Cairns","year":"1991","journal-title":"Circulation"},{"key":"R4-2-20210207","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"R5-2-20210207","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archinte.156.4.409","article-title":"The stroke prevention in atrial fibrillation investigators.","volume":"156","year":"1996","journal-title":"Arch Intern Med"},{"key":"R6-2-20210207","doi-asserted-by":"crossref","first-page":"511S","DOI":"10.1378\/chest.114.5_Supplement.511S","article-title":"Hemorrhagic complications of anticoagulant treatment","volume":"114","author":"Levine","year":"1998","journal-title":"Chest"},{"key":"R7-2-20210207","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000015958","article-title":"Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis","volume":"9","author":"Hart","year":"1999","journal-title":"Cerebrovasc Dis"},{"key":"R8-2-20210207","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"R9-2-20210207","first-page":"1505","article-title":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.","volume":"323","year":"1990","journal-title":"N Engl J Med"},{"key":"R10-2-20210207","first-page":"527","article-title":"Final results.","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"R11-2-20210207","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"R12-2-20210207","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/eurheartj\/ehl492","article-title":"Anticoagulants in heart disease: current status and perspectives","volume":"28","author":"De Caterina","year":"2007","journal-title":"Eur Heart J"},{"key":"R13-2-20210207","doi-asserted-by":"crossref","first-page":"448.e1","DOI":"10.1016\/j.amjmed.2005.10.057","article-title":"Quality of life in patients with atrial fibrillation: a systematic review","volume":"119","author":"Thrall","year":"2006","journal-title":"Am J Med"},{"key":"R14-2-20210207","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"R15-2-20210207","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clpt.2003.10.001","article-title":"Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin","volume":"75","author":"Kamali","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R16-2-20210207","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1053\/euhj.2000.2300","article-title":"Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications","volume":"22","author":"Frykman","year":"2001","journal-title":"Eur Heart J"},{"key":"R17-2-20210207","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/09537109309013225","article-title":"The basic pharmacology of ticlopidine and clopidogrel","volume":"4","author":"Schror","year":"1993","journal-title":"Platelets"},{"key":"R18-2-20210207","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R19-2-20210207","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.CIR.101.6.590","article-title":"A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents","volume":"101","author":"Muller","year":"2000","journal-title":"Circulation"},{"key":"R20-2-20210207","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS)","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"R21-2-20210207","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"R22-2-20210207","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JANA"},{"key":"R23-2-20210207","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"R24-2-20210207","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"R25-2-20210207","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"R26-2-20210207","first-page":"3","article-title":"The biochemical basis of warfarin therapy","volume":"214","author":"Suttie","year":"1987","journal-title":"Adv Exp Med Biol"},{"key":"R27-2-20210207","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.V97.8.2308","article-title":"Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex","volume":"97","author":"Rezaie","year":"2001","journal-title":"Blood"},{"key":"R28-2-20210207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(03)00030-6","article-title":"Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux)","volume":"109","author":"Samama","year":"2003","journal-title":"Thromb Res"},{"key":"R29-2-20210207","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"R30-2-20210207","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"R31-2-20210207","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"B\u00fcller","year":"2003","journal-title":"N Engl J Med"},{"key":"R32-2-20210207","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"R33-2-20210207","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Bassand","year":"2007","journal-title":"Eur Heart J"},{"key":"R34-2-20210207","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","article-title":"ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R35-2-20210207","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"R36-2-20210207","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, noninferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"key":"R37-2-20210207","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/13543784.17.5.773","article-title":"Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders","volume":"17","author":"Prandoni","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"R38-2-20210207","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0037-1612989","article-title":"Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects","volume":"87","author":"Sarich","year":"2002","journal-title":"Thromb Haemost"},{"key":"R39-2-20210207","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.31.3.294","article-title":"Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans","volume":"31","author":"Eriksson","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"R40-2-20210207","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(03)00249-4","article-title":"The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review","volume":"109","author":"Gustafsson","year":"2003","journal-title":"Thromb Res"},{"key":"R41-2-20210207","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003088-200342050-00005","article-title":"No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers","volume":"42","author":"Johansson","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R42-2-20210207","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1358\/dof.2005.030.09.938760","article-title":"Dabigatran\/dabigatran etexilate","volume":"30","author":"Sorbera","year":"2005","journal-title":"Drugs Future"},{"key":"R43-2-20210207","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Eriksson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R44-2-20210207","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R45-2-20210207","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1538-7836.2004.00890.x","article-title":"Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I","volume":"2","author":"Eriksson","year":"2004","journal-title":"J Thromb Haemost"},{"key":"R46-2-20210207","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/vhrm.2006.2.1.49","article-title":"Ximelagatran: direct thrombin inhibitor","volume":"2","author":"Ho","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"R47-2-20210207","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"R48-2-20210207","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"R49-2-20210207","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"R50-2-20210207","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf"},{"key":"R51-2-20210207","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R52-2-20210207","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"R54-2-20210207","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R55-2-20210207","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R56-2-20210207","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R58-2-20210207","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R59-2-20210207","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1160\/TH07-04-0312","article-title":"Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber","volume":"98","author":"Zafar","year":"2007","journal-title":"Thromb Haemost"},{"key":"R60-2-20210207","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01244665-200906000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:18:31Z","timestamp":1786371511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01244665-200906000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.2459\/jcm.0b013e3283249aee","relation":{},"ISSN":["1558-2027"],"issn-type":[{"value":"1558-2027","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}